Trial Profile
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 02 Mar 2022
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Ipilimumab (Primary) ; Lirilumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms ECHO-208
- Sponsors Incyte Corporation
- 02 Feb 2022 According to ClinicalTrials.gov record, protocol has been amended as treatment arm changed from 2 to 7
- 02 Feb 2022 Status changed from completed to discontinued.
- 01 Feb 2021 Status changed from active, no longer recruiting to completed.